Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes.

被引：3
|
作者：
Vaidvanathan, S [1 ]
Zhao, C [1 ]
Yeh, C [1 ]
Dieterich, H [1 ]
机构：
[1] Novartis Pharma AG, Novartis Pharmaceut, E Hanover, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.042
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P12 / P12
页数：1
相关论文
共 50 条
  • [41] Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
    Stanton, A
    Jensen, C
    Nussberger, J
    OBrien, E
    HYPERTENSION, 2003, 42 (06) : 1137 - 1143
  • [42] Aliskiren, an oral direct renin inhibitor, has no effect on the pharmacokinetics or pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang, H. A.
    Vaidyanathan, S.
    Yeh, C.
    Dieterich, H. A.
    Dole, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S59 - S60
  • [43] Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial
    Uzu, Takashi
    Araki, Shin-ichi
    Kashiwagi, Atsunori
    Haneda, Masakazu
    Koya, Daisuke
    Yokoyama, Hiroki
    Kida, Yasuo
    Ikebuchi, Motoyoshi
    Nakamura, Takaaki
    Nishimura, Masataka
    Takahara, Noriko
    Obata, Toshiyuki
    Omichi, Nobuyuki
    Sakamoto, Katsuhiko
    Shingu, Ryosuke
    Taki, Hideki
    Nagai, Yoshio
    Tokuda, Hiroaki
    Kitada, Munehiro
    Misawa, Miwa
    Nishiyama, Akira
    Kobori, Hiroyuki
    Maegawa, Hiroshi
    PLOS ONE, 2016, 11 (12):
  • [44] Effectiveness of the Direct Renin Inhibitor, Aliskiren, in Patients With Resistant Hypertension
    Yoshitomi, Yuji
    Kawanishi, Ken-ichi
    Yamaguchi, Akihisa
    Sakurai, Shun-ichiro
    Minai, Kazuo
    Ishii, Toshikazu
    Tarutani, Yasuhiro
    Tsujibayashi, Takashi
    Kaneki, Masashi
    Saitou, Yuichi
    Suwa, Satoru
    INTERNATIONAL HEART JOURNAL, 2013, 54 (02) : 88 - 92
  • [45] Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
    Kolterman, OG
    Kim, DD
    Shen, L
    Ruggles, JA
    Nielsen, LL
    Fineman, MS
    Baron, AD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (02) : 173 - 181
  • [46] Exenatide in adolescent patients with type 2 diabetes: Pharmacokinetics, pharmacodynamics, safety, and
    Malloy, Jaret
    Guan, Xuesong
    Kothare, Prajakti.
    Capparelli, Edmund
    Fineman, Mark
    DIABETES, 2008, 57 : A145 - A145
  • [47] ALISKIREN (AN ORAL DIRECT RENIN INHIBITOR) IS EFFECTIVE AND WELL TOLERATED COMPARED TO RAMIPRIL IN CHINESE HYPERTENSIVE PATIENTS
    Zhu, J.
    Ritter, S.
    Tu, Y.
    Wang, R.
    JOURNAL OF HYPERTENSION, 2009, 27 : S271 - S271
  • [48] Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: A pooled analysis of 1093 patients with hypertension
    Taylor, Addison A.
    Anderson, David R.
    Arora, Vipin
    Satlin, Andrew
    Prescott, Margaret F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 370A - 370A
  • [49] Effectiveness and safety of lispro in the management of patients with type II diabetes.
    Ross, S
    Zinman, B
    Campos, R
    Strack, T
    DIABETES, 1997, 46 : 1254 - 1254
  • [50] Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: A pooled analysis of 1612 patients with hypertension
    Gradman, Alan H.
    Flack, John M.
    Arora, Vipin
    Zhang, Jack
    Anderson, David R.
    Keefe, Deborah L.
    Satlin, Andrew
    Prescott, Margaret F.
    CIRCULATION, 2006, 114 (18) : 773 - 773
12345